Analysts Expect Evoke Pharma Inc (NASDAQ:EVOK) to Post -$0.12 Earnings Per Share

Wall Street analysts expect Evoke Pharma Inc (NASDAQ:EVOK) to report earnings per share (EPS) of ($0.12) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Evoke Pharma’s earnings. Evoke Pharma reported earnings of ($0.14) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 14.3%. The firm is expected to report its next earnings results on Thursday, August 15th.

On average, analysts expect that Evoke Pharma will report full year earnings of ($0.35) per share for the current financial year. For the next fiscal year, analysts forecast that the company will post earnings of ($0.19) per share. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03.

EVOK has been the topic of several research reports. Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a research report on Tuesday. HC Wainwright reissued a “hold” rating on shares of Evoke Pharma in a research report on Friday, August 9th. Finally, ValuEngine raised Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Evoke Pharma during the first quarter worth about $118,000. Marshall Wace LLP purchased a new stake in shares of Evoke Pharma during the first quarter worth about $139,000. Citadel Advisors LLC purchased a new stake in shares of Evoke Pharma during the second quarter worth about $37,000. Finally, BlackRock Inc. increased its position in shares of Evoke Pharma by 5.5% during the fourth quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock worth $207,000 after acquiring an additional 4,392 shares during the last quarter. 7.40% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:EVOK traded up $0.02 during mid-day trading on Thursday, hitting $0.86. The company had a trading volume of 135,076 shares, compared to its average volume of 712,145. The business has a fifty day simple moving average of $0.89. Evoke Pharma has a 1 year low of $0.50 and a 1 year high of $3.40. The company has a market capitalization of $19.31 million, a price-to-earnings ratio of -1.87 and a beta of 1.62.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Further Reading: What is the yield curve?

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.